Nanotechnology Now - Press Release: Cutting-edge combination shows promise in patients with chemotherapy-resistant urothelial cancer

Home > Press > Cutting-edge combination shows promise in patients with chemotherapy-resistant urothelial cancer

Abstract:
A combination of two types of cancer-fighting treatments – the immunotherapy agent pembrolizumab and a nanoparticle-bound form of the chemotherapy drug paclitaxel – may provide an urgently needed new treatment approach for patients who do not respond to or can't receive standard chemotherapy for advanced urothelial cancers, reports a preliminary study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Cutting-edge combination shows promise in patients with chemotherapy-resistant urothelial cancer

Alphen aan den Rijn, Netherlands | Posted on November 4th, 2022

"While still experimental, the combination of these two agents offers an efficacious and feasible alternative for a group of patients for whom we don't otherwise have effective treatment options," comments Irene Tsung, MD, of University of Michigan, Ann Arbor.

Half of patients have at least a partial response to anti-PD1 plus nab-paclitaxel

Urothelial cancer (UC) is a type of cancer developing in the cells lining the urinary tract; most bladder cancers are UCs. The standard treatment for advanced UC is chemotherapy with platinum-based agents such as cisplatin. However, many patients do not respond to this form of chemotherapy, or cannot receive it due to other medical conditions.

Dr. Tsung and colleagues evaluated an innovative combination of two cancer treatments for use in this situation. Pembrolizumab is an anti-PD1 antibody that blocks the "programmed cell death" pathway. Developed to treat other types of advanced cancers, pembrolizumab has been used with some success in patients with advanced or metastatic UC. Nanoparticle-albumin-bound (nab) paclitaxel is a relatively new formulation of an important chemotherapy drug, created using nanotechnology to enhance effectiveness and reduce complications.

Dr. Tsung and colleagues report on 36 patients with platinum-refractory or platinum-ineligible UCs who received this combination of drugs. The first treated patients experienced a high rate of severe adverse events, such as fatigue and anemia. This problem was alleviated by reducing the starting dose of nab-paclitaxel.

Overall response rate to pembrolizumab plus nab-paclitaxel was 50%. Three patients had complete responses while 15 had partial responses; 31 of the 36 patients had at least some tumor shrinkage after combination therapy. The researchers note that the 50% response rate was substantially higher than in previous studies of pembrolizumab alone for refractory UC.

Other outcomes also showed encouraging results: median duration of response was 4.4 months, while median time without cancer progression was 6.8 months. Overall median survival time was 18.2 months.

After the nab-paclitaxel starting-dose reduction, few patients experienced severe adverse events. Ten patients had immune-related adverse events, which is consistent with previous use of single-agent anti-PD1 and other immunotherapy agents.

"[T]he combination of nab-paclitaxel and anti-PD 1 therapy offers an efficacious and feasible option for advanced urothelial cancer patients who cannot receive cisplatin or are platinum-refractory," Dr. Tsung and coauthors write. They note that both are readily available, FDA-approved treatments with known side effect profiles. At a time when new treatment options are rapidly evolving, the researchers call for "continued exploration" of strategies combining chemotherapy and immunotherapy for advanced UC.

####

About Wolters Kluwer Health
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,800 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

About The Journal of Urology®

The Official Journal of the American Urological Association (AUA), and the most widely read and highly cited journal in the field, The Journal of Urology® brings solid coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of urology. This premier journal presents investigative studies on critical areas of research and practice, survey articles providing brief editorial comments on the best and most important urology literature worldwide and practice-oriented reports on significant clinical observations. The Journal of Urology® covers the wide scope of urology, including pediatric urology, urologic cancers, renal transplantation, male infertility, urinary tract stones, female urology and neurourology.

About the American Urological Association

Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 23,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health care policy. To learn more about the AUA visit: www.auanet.org

For more information, please click here

Contacts:
Josh DeStefano
Wolters Kluwer Health

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: